Pierides A M, Ellis H A, Dellagrammatikas H, Scott J E, Norman A W
Arch Dis Child. 1977 Jun;52(6):464-72. doi: 10.1136/adc.52.6.464.
Three children with azotaemic renal osteodystrophy were treated with 1,25-dihydroxycholecalciferol (1,25(OH)2D3). All showed clinical, biochemical, and radiological improvement within 6 months of starting treatment. There were no complications. The dose of 1,25(OH)2D3 required was 0-5 microgram per day for 2 children aged 22 and 30 months, and 2 microgram per day for a 15-year-old boy. 2 of the patients were receiving phenobarbitone and phenytoin and in one of them prior treatment with dihydrotachysterol 0-5 mg daily and 6 microgram 1alpha-hydroxycholecalciferol (1alphaOHD3) daily had failed to induce improvement. In one patient, in whom serial iliac bone samples were available, 2 microgram 1,25(OH)2D3 resulted in histological improvement in previously severe osteomalacia. 1,25(OH)2D3 appears to be an effective and safe drug in the treatment of uraemic osteodystrophy.
三名氮质血症性肾性骨营养不良患儿接受了1,25 - 二羟胆钙化醇(1,25(OH)₂D₃)治疗。开始治疗后的6个月内,所有患儿均出现临床、生化及影像学改善。未出现并发症。两名22个月和30个月大的患儿所需的1,25(OH)₂D₃剂量为每日0.5微克,一名15岁男孩为每日2微克。两名患者正在接受苯巴比妥和苯妥英治疗,其中一名患者此前每日服用0.5毫克二氢速甾醇和每日6微克1α - 羟胆钙化醇(1αOHD₃)治疗均未改善。在一名可获取连续髂骨样本的患者中,2微克1,25(OH)₂D₃使先前严重的骨软化症在组织学上得到改善。1,25(OH)₂D₃似乎是治疗尿毒症性骨营养不良的一种有效且安全的药物。